Workshop Day

Workshop A 9.00 – 12.00

Advancing Screening Methods for Both Targets & TCR Molecules to Boost Validation Strategy & Guarantee Patient Safety


Since TCR therapies have been known to cause off-target toxicities, it is vital for patient safety to ensure targets are localized and restricted to tumor cells, meanwhile TCRs are specific to antigen targets. Next-generation TCR and target screening methods and technologies can provide the optimal validation to prevent cross-reactivity and off-target effects to secure therapy safety.

  • Developing effective assays and technology to screen for TCR specificity and cross-reactivity to enable high TCR quality
  • Enhancing analytical methods to measure TCR affinity to prevent toxicity
  • Validating tumor specificity of target antigens to ensure it is safe but effective
  • Moving forward towards the entry-into-human milestone, ensuring the predictive value of the models, assays and endpoints for PD, PK/PD and safety assessment
  • Identifying Cryptic/Dark Antigens from Tumor Immunopeptidomes

Lunchtime Refreshments 12.00 – 1.00

Workshop B 1.00 – 4.00

Leveraging Conditional Activation to Provide Targeted Tumor Killing & Guarantee Therapy Safety

  • David Scheinberg Director, Experimental Therapeutics Center, Memorial Sloan Kettering Cancer Center


The hostile tumor microenvironment continues to create a barrier to cell therapy efficacy in solid tumors. Use of gating and switch technology is on the rise to generate localized and specific secretion of factors to provide enhanced killing in the solid tumor microenvironment and hinder T-cell exhaustion.

  • Engineering cells to implement a gated switch system to allow control of TCR-T cells in vivo
  • Utilizing switches to control and activate cells at the tumor site to guarantee specificity and improved safety
  • Leveraging switches to enable enhanced tumor cell killing following stimulation at the tumor site